Biotech | November 15, 2025
Merck to acquire Cidara Therapeutics for $9.2 billion
Diversifying its portfolio to include late-phase antiviral agent
Diversifying its portfolio to include late-phase antiviral agent
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Revenue increased 11.4 per cent to Rs. 8,545 crore
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Subscribe To Our Newsletter & Stay Updated
